Nukkleus received a delisting notice from Nasdaq on November 13, 2024, for failing to meet the minimum $15 million market value of publicly held shares and $50 million market value of listed securities requirements. The company plans to appeal this decision to a Nasdaq Hearings Panel by November 20, which will stay the suspension of its securities pending the panel's decision.During the appeal process, Nukkleus' common stock (NUKK) and warrants (NUKKW) will continue trading on The Nasdaq Global Market. However, there's no assurance that the appeal will be successful or that the company will regain compliance with the listing rules.Separately, on November 8, Nukkleus entered into a Conversion Agreement with X Group Fund of Funds to convert $771,085 of debt into 319,952 shares of common stock. The company also issued a warrant with an exercise price of $2.41. These transactions were made to accredited investors under exemptions from Securities Act registration requirements.

Nukkleus received a delisting notice from Nasdaq on November 13, 2024, for failing to meet the minimum $15 million market value of publicly held shares and $50 million market value of listed securities requirements. The company plans to appeal this decision to a Nasdaq Hearings Panel by November 20, which will stay the suspension of its securities pending the panel's decision.During the appeal process, Nukkleus' common stock (NUKK) and warrants (NUKKW) will continue trading on The Nasdaq Global Market. However, there's no assurance that the appeal will be successful or that the company will regain compliance with the listing rules.Separately, on November 8, Nukkleus entered into a Conversion Agreement with X Group Fund of Funds to convert $771,085 of debt into 319,952 shares of common stock. The company also issued a warrant with an exercise price of $2.41. These transactions were made to accredited investors under exemptions from Securities Act registration requirements.